Background: Benznidazole is one of the two most effective antiparasitic drugs for Chagas' disease treatment. However, knowledge about its toxicity profile is mostly based on post-marketing observational studies.
Introduction
Chagas' disease is a chronic anthropozoonotic disease caused by the protozoan Trypanosoma cruzi and it is most frequently transmitted through a vectorial route. However, it is also a major public health problem in endemic and non-endemic countries given its transmissibility from mother to child or through blood products and organ transplants. Outbreaks with oral transmission have also been described. [1] [2] [3] It is estimated that 6-7 million people could be infected worldwide and 20%-30% of them could develop a potentially life-threatening cardiac condition. 1 The treatment in acute cases is very effective whereas in chronic disease the effectiveness has been highly debated. [4] [5] [6] There is a general understanding that parasitic persistence increases the risk of cardiac lesions in chronically infected patients and therefore parasite eradication may be necessary in the early stages of the disease. 7 On the other hand, the advanced cardiac stage is irreversible and treatment of this stage is futile. The BENEFIT trial supported this conclusion in that it did not show significant morbidity or mortality reduction with antiparasitic treatment at the advanced cardiac stage. 5, 8, 9 However, this study did not provide answers about the long-term effectiveness of the antiparasitic approach in early stages of the chronic disease. In recent years the evidence from observational studies has supported treating most chronic patients with the available antiparasitic drugs. 10, 11 At the moment, the most effective drugs to treat Chagas' disease are benznidazole and nifurtimox. Both drugs have shown poor tolerance, significant adverse reactions (ARs) and high treatment suspension rates. They were registered and have been used in clinical practice since their launch in the 1970s with little understanding of their mechanism of action and toxicity. Early comprehensive preclinical toxicological investigations were conducted for nifurtimox whereas no equivalent information has been available for benznidazole. 12 Given that no pre-marketing safety studies were performed, most of the available knowledge on human safety is based on post-marketing retrospective observational studies. Very few studies have been designed to offer systematic post-marketing surveillance, which could explain the variability in side effect reports between different groups in addition to those with racial or genetic differences.
Expert forums have discussed the possibility of different safety profiles depending on the drug manufacturer. This question was raised mostly when ELEA Laboratories took responsibility for production after a dramatic period of 2 years when there was a lack of benznidazole stock worldwide between 2011 and 2013. 13 There were some concerns that the drugs produced by the Brazilian state-owned laboratory LAFEPE and those from ELEA Laboratories in Argentina may have different toxicity profiles, even if some retrospective studies did not observe any significant differences in treatment withdrawals. 14 The aim of this study is to offer a systematic evaluation of safety in a prospective study of the drug manufactured by ELEA Laboratories in chronically infected adults.
Patients and methods

Study design
From 2013 to 2016 we conducted two prospective, open-label and single-centre clinical trials in the International Health Department of the Hospital Clinic of Barcelona. CINEBENZ was designed to study the population pharmacokinetics of benznidazole and BIOMARCHA monitored cardiac biomarkers before and after treatment (EUDRACT 2011-002900-34 and 2012-002645-38, respectively, and clinicaltrials.gov NCT01755403 and NCT01755377, respectively). The protocols were approved by the Ethics Committee of the Hospital Clinic of Barcelona and AEMPS (the Spanish Agency of Medicines and Medical Devices) and the trials were conducted in accordance with the Declaration of Helsinki and national and institutional standards. Before inclusion in the studies, all patients provided written informed consent. Both studies had the same treatment and follow-up protocol during treatment and the ARs of both studies were analysed together.
Eligible subjects met the inclusion criteria of being at least 18 years old, diagnosed by two different positive Trypanosoma cruzi serological tests, not having received treatment before and not having advanced cardiac disease. Exclusion criteria were hypersensitivity to benznidazole, difficulties following up, immunodeficiency, hepatic or renal impairment, cardiac disease of other origin, pregnancy or lactation. Enrolled subjects received treatment with 5 mg/kg/day benznidazole orally, with or without food, in two divided doses for 8 weeks, with a maximum of 400 mg/day (Abarax V R , ELEA Laboratories, Argentina).
We selected all subjects attending health facilities meeting the inclusion and exclusion criteria using a consecutive sampling strategy. Patients were followed up fortnightly with clinical review and a blood test. The clinical review consisted of an open interview plus exhaustive structured questioning, a physical examination and vital sign measurements. Patients had a contact telephone number available 24 h per day and they could be seen ad hoc in the clinic if needed. As per site protocol at the time, no food restriction was applied but commitment to avoid alcohol during treatment was required.
Data management and statistical analysis
Data collection and management were performed using OpenClinica open source software, version 2.0.3.1. (Copyright V C OpenClinica LLC and collaborators, Waltham, MA, USA; www.OpenClinica.com). Data were described using frequencies for discrete variables and median (IQR) for continuous variables. AR incidence rates and confidence intervals based on Poisson distribution were estimated. Multilevel Poisson regression models were employed to assess the fortnightly incidence rate ratio (IRR) of ARs. 15 To assess the existence of a time trend of the IRR of ARs, the same models were performed using a day instead of a fortnight. Following clinical criteria, all models were adjusted by sex and age. The significance level was set at 0.05. The analysis was carried out using Stata Statistical Software: Release 14 (StataCorp, College Station, TX, USA; 2015).
Results
Out of 100 eligible patients, 99 received treatment with benznidazole and one patient declined to participate. Baseline demographic and clinical characteristics can be seen in Table 1 . In the cohort, 97 patients (98.0%) were Bolivian, 73.7% were women and the median age was 36 (IQR 9). Regarding Chagas' disease form, six had a mild heart disease and the rest did not have any evidence of organic disease. Out of 99 participants, 26 patients (26.3%) did not complete treatment: 22 owing to ARs; 2 were lost to follow-up; and 2 had withdrawal criteria with severe consequences, 1 for pregnancy and 1 for epilepsy relapse. See Table 2 .
Eighty-five patients out of 99 (85.9%) had 305 ARs. Among patients with ARs, each patient had a median of 3 ARs (IQR 1). Following the WHO toxicity grade scale, the majority of ARs were mild (n " 273, 89.5%), 30 were moderate (9.8%) and two were severe (0.7%). The median time to onset of the first AR was 9 days Benznidazole toxicity in chronic Chagas' disease JAC Aldasoro et al.
(IQR 12) and the majority of the ARs (81.8%) appeared in the first month of treatment. See Figure 1 . The median duration of all ARs was 12 days (IQR 9.5). One hundred and thirty-six (44.6%) of the ARs required some intervention or medication whereas the rest resolved with no medical treatment. Among the 85 patients who had ARs, the majority had dermatological (74%) or neuropsychiatric symptoms (60%), followed by digestive (40%), general (32%), musculoskeletal (21%) and reproductive system (5%) disorders and only one patient had pulmonary symptoms. See Table 3 .
The ARs leading to suspension of treatment were: rash (n " 7), arthritis (n " 3), peripheral neuropathy (n " 3), anxiety (n " 3), fever (n " 2), general malaise (n " 1), angioedema and pulmonary symptoms (n " 1), drug rash with eosinophilia and systemic symptoms (DRESS) syndrome (n " 1) and treatment intolerance in the context of consumption of a high dose of alcohol (n " 1). Among them, four patients decided to stop treatment before medical advice and three other patients suspended treatment because they were unable to return to the clinic for follow-up. By site protocol, we suspended treatment of patients reporting fever, peripheral neuropathy (including ageusia) and arthritis. The rest of the patients who did not complete treatment had unexpected or severe ARs. See Table 2 .
Among patients who did not complete treatment, the median duration of treatment was 25.5 days (IQR 27) (Figure 2 ) and the median cumulative dose of benznidazole at the end of treatment was 7450.0 mg (IQR 9400.0). Among patients who completed treatment, the median duration of treatment was 57 days (IQR 6) and the median cumulative dose at the end of treatment was 18 350.0 mg (IQR 5950.0).
Ten unexpected ARs were recognized during treatment. Four cases of psychiatric symptoms were observed; one severe, two moderate and one mild. The cases involved sleeping disorders, anxiety and panic attacks and, in the most severe cases, tremor and persecutory delusions. One case had a history of anxiety and one patient had personal difficulties during treatment. No other explanation was found in the two other cases. There were two cases of amenorrhoea during treatment. One woman missed only one cycle, whereas the other missed three cycles. Pregnancy tests were negative, there was no history of irregular menstrual periods and no other reason was found. Two men reported erectile dysfunction during treatment after 8 and 36 days of treatment. The dose until onset was 2200 and 11 850 mg and symptoms lasted between 100 and 148 days, respectively. Only one patient recognized personal issues at the time and no vascular or hormonal disorders were found. Finally, one patient presented with bronchospasm, basal lung infiltrations in the chest X-ray and basal tree-in-bud nodules in the CT scan with no other explanation after the study. See Table 2 .
We had blood test data for 98 out of 99 patients during treatment and 61 patients (62.2%) had blood test alterations. The majority of blood test abnormalities were mild and none of them led to treatment suspension by themselves. Two cases with moderate increases in transaminases could not be contacted to stop treatment and by the next appointment liver tests were back to normal. All the severe blood results were related to DRESS syndrome and treatment was suspended for clinical reasons before blood tests were acknowledged. See Table 4 . The median time to onset of alterations in liver function tests was 28.5 days (IQR 35) whereas white blood cell disturbances appeared earlier with a median time to onset of 14 days (IQR 14).
The overall AR incidence rate was 9.2 ARs (95% CI 8.2-10.3) per 10 person-fortnights. The incidence rate for mild ARs per 10 person-fortnights was 8.2 (95% CI 7.3-9.3), 0.9 for moderate ARs (95% CI 0.6-1.3) and 0.1 for severe ARs (95% CI 0-0.2). Dermatological and neuropsychiatric reactions had the highest incidence rate among different AR types. See Table 5 .
A multilevel Poisson regression analysis adjusted by age and sex showed strong evidence that the overall incidence rate was much higher in the first fortnight with a decreasing trend in the following fortnights. This pattern was similar in all different categories of AR except for musculoskeletal ARs for which there was no evidence of different incidence rates among the four fortnights (P " 0.3005). See Table 5 .
There are two types of ARs that tend to appear later during treatment: arthritis and peripheral neuropathy. We observed 11 cases of possible peripheral neuropathy. Four of them were subtle and non-typical: bitter taste (n " 1), temporary burning feeling in hands and feet (n " 1) and intermittent dysaesthesia in hands (n " 2). The time to onset in these cases varied between 5 and 32 days and no treatment suspension was medically advised. The other seven cases had established peripheral neuropathy, two with ageusia and five with peripheral numbness or neuropathic pain. The median time to onset in these cases was 46 days (IQR 13) and the median dose to onset was 15 350 mg (IQR 4550). All cases receiving treatment were advised to discontinue treatment. The median duration of symptoms was 31 days (IQR 48). One patient had an electromyoneurography where small fibre polyneuropathy was observed and symptoms lasted 321 days. Arthritis was observed in six cases: two monoarthritis, two polyarthritis, one migratory and one additive case. Large joints, such as knees and shoulders, were affected in all cases. The patients with polyarthritis and migratory arthritis also presented with wrist, hip and ankle involvement and the migratory arthritis case was the only one in which metacarpophalangeal joints were affected. All cases of arthritis appeared after at least 31 days of treatment (median 33, IQR 23) with a median cumulative dose of 9300 mg (IQR 5750) and all cases were women.
Finally, there was some evidence that women may have a higher incidence of ARs compared with men when adjusted by age (P " 0.0164). Overall, taking into account all ARs, women had a 53% higher incidence of ARs than men (95% CI 1.08-2.17). (81) 5 (19) 0 (0) 32 (10) 29 (91) 3 (9) 4 (13) 12 (22) 3575 (5250) 15 (23) asthenia 16 (100) 0 (0) 0 (0) 16 (50) 15 (94) 1 (6) 0 (0) 8 (28) 1675 (6575) 15 ( 5 (16) 4 (80) 1 (20) 3 (60) 16 (11) 4050 (3700) 24 (27) hyporexia 4 (100)
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e Other skin disorders: three cases of angioedema (one mild and two moderate), one case of DRESS syndrome (severe), three cases of skin peeling (mild), two cases of skin plaques or thickening (mild), one case of chronic hyperpigmentation (mild) and one case of distal swelling in ankles (moderate).
f Other neuropsychiatric ARs: two cases of emotional lability (one mild, one moderate) and one case of persecutory delusion (mild).
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Discussion
The results of this study are in agreement with most previous observational studies showing poor tolerance of benznidazole. 14, [16] [17] [18] [19] [20] With the most widely used dosage of 5 mg/kg/day for 60 days there is a high frequency of ARs with a significant disease burden for patients. Only 14% of patients were free of ARs whereas the majority had several consecutive or simultaneous ARs and suffered from them for a median of 12 days. Most ARs were mild, but significant ARs appeared in up to 10% of the cases. Skin reactions, neuropsychiatric ARs (including headache) and digestive symptoms were, in this order, the most frequent ARs involving 82% of all ARs.
The most severe ARs presented in this study have already been described in the literature. Eight cases of DRESS syndrome have been described, two of them overlapping with Stevens-Johnson syndrome and toxic epidermal necrolysis; another case of Stevens-Johnson syndrome and two cases of acute generalized exanthematous pustulosis have also been reported. 14, 18, 19, 21, 22 Thus, life-threatening skin ARs, even though uncommon, are not rare and this underlines the need for close benznidazole treatment monitoring. In our cohort, angioedema appeared in 3% of exposed patients with the only severe case being the patient with DRESS syndrome. Molina et al.
14 observed angioedema in 1.1% of their patients whereas Miller et al. 16 described it in up to 20% of their cohort. Patients in this latter study were mostly from Northern and Central America and different ethnicity or Trypanosoma genotype may explain the difference in AR prevalence. 19 Eighty percent of the patients with ARs had their first AR in the first 30 days of treatment, which supports the theory that most ARs are secondary to hypersensitivity reactions. 19 However, it is consistent in all studies that some cumulative dose or treatment duration is necessary for arthritis and peripheral neuropathy to appear. In the previous arthritis series published by our group, arthritis symptoms appeared after at least 40 days of treatment Benznidazole toxicity in chronic Chagas' disease JAC and a cumulative dose of 7500 mg. 23 In the current study, all cases of arthritis appeared after at least 31 days of treatment and a cumulative dose of 7250 mg, and typical peripheral neuropathy after at least 22 days of treatment and a cumulative dose of 5850 mg. These results support the theory that arthritis and peripheral neuropathy may be secondary to toxicity produced by benznidazole and therefore 30 days of treatment would prevent most of the cases. 24 However, data from this study do not support the threshold of 18 g described in some other studies as a threshold for toxicity-driven ARs. 25 Our results do not agree either with previous study results in which bone marrow depression appeared late in treatment as white blood cell disturbances were observed with a median time to onset of 14 days. 24 We have observed some unexpected ARs that have not been described in previous studies. Even if sleeping disorders, either insomnia or sleepiness, have already been reported in some cohorts, it is the first time to our knowledge that psychiatric symptoms, such as anxiety, panic attacks, emotional lability and persecutory delusions, have been described. 14, 16, 18 These results may suggest some central nervous system effect by benznidazole. Some patients also presented with erectile dysfunction or delay in menstrual cycle with no other good explanation for these symptoms. One patient had bronchospasm and bibasal lung infiltration that disappeared after treatment suspension and could not be explained by her medical history. None of the ARs had any permanent consequences except one case of erythema dyschromicum perstans in both legs diagnosed by histopathology 6 months after having a moderate skin rash reaction. Finally, we suspended treatment in a patient with an ectopic pregnancy during treatment. She had other risk factors, such as a long history of infertility and exposure to 2 days of mequitazine. Mequitazine has not demonstrated any teratogen effect in animal studies, but information in humans is insufficient to ensure safety in pregnancy. On the other hand, some studies in pregnant rats observed that benznidazole could cross the placental barrier and reach the foetuses. 12 The association between the ARs and benznidazole could not be ruled out in all those cases. Future pharmacovigilance data will be needed to establish whether there is any real association.
The treatment suspension rate was 26% in our study with free and flexible healthcare access. However, six patients reported difficulties in having a safe social environment during the treatment: three patients had difficulties attending clinical review owing to work-related limitations and three other patients could not cope and felt ashamed because of stigmatizing skin reactions in an already vulnerable population. These results manifest how social support has an impact on the effectiveness of treatment and migrants are exposed to healthcare access limitations attributable to the lack of social support. 26, 27 Our study may have a generalizability limitation given almost all the patients were migrants from Bolivia. Race and genetics seem to be significant in drug ARs and even some human leucocyte antigen alleles have been proposed to be associated with benznidazole-related ARs. 19, 28 Moreover, their migrant status may determine their social support and health access during treatment compared with different locations.
It is estimated that over one million people are affected by cardiac Chagas' disease worldwide and, based on the latest studies, mortality in 5 years despite treatment could reach 17%-18%. 8, 29 These results underline the urgent need for long-term studies with strong clinical outcomes to understand treatment efficacy as a secondary prevention or therapeutic treatment. It is also critical to optimize treatment with benznidazole considering it will still be part of the treatment in the near foreseeable future. Combined drug therapy or different dosages need to be evaluated to achieve the maximum efficacy with the minimum toxicity. 30 At the moment we have reached a point where there is no effective treatment for advanced Chagas' disease and antiparasitic drug toxicity is intolerably high as a potential secondary preventive treatment in chronically infected patients.
